Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 25 March, 2020

Societe Generale SA

Form 8.3 - Allergan plc

RNS Number : 5336H
Societe Generale SA
25 March 2020
 

  Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

Société Générale S.A.

Companydealtin

   Allergan plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.0001 ordinary shares

Date of dealing

24/03/2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

2,694,757

0.82

57,878

0.02

(2) Derivatives (other than options)

0

0.00

1,417,017

0.43

(3) Options and agreements to purchase/sell

58,500

0.02

0

0.00

Total

*5,733,500

*1.74

1,474,895

0.45

 

* Include the holding of 2,980,243 shares on borrow products

 

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

100

173.02

Purchase

100

172.72

Purchase

50

172.66

Purchase

50

172.66

Purchase

36

170.71

Purchase

64

170.71

Purchase

43

171.94

Purchase

16

171.94

Purchase

23

171.94

Purchase

18

171.94

Purchase

100

173.04

Purchase

50

172.56

Purchase

50

172.56

Purchase

100

172.42

Purchase

100

172.13

Purchase

100

171.87

Purchase

50

171.8

Purchase

50

171.79

Purchase

30

173.73

Purchase

454

173.580463

Purchase

212

173.355472

Purchase

8,197

170.85

Purchase

2,646

170.85

Purchase

16,351

170.85

Purchase

50,808

167.7

Purchase

100

170.85

Purchase

2,528

170.85

Purchase

594,341

167.7

Purchase

10,625

170.85

Sale

100

170.94

Sale

100

172.21

Sale

100

172.07

Sale

100

173.45

Sale

63

172.33

Sale

37

172.33

Sale

100

171.54

Sale

100

173.14

Sale

100

172.95

Sale

100

172.87

Sale

100

174.59

Sale

100

172.86

Sale

62

172.4

Sale

100

172.32

Sale

69

170.76

Sale

100

173.65

Sale

100

173.44

Sale

29

173.03

Sale

71

173.03

Sale

100

173.01

Sale

58

172.25

Sale

42

172.25

Sale

100

173.03

Sale

100

173.12

Sale

100

172.07

Sale

32

172.07

Sale

50

174.03

Sale

100

171.92

Sale

100

172.95

Sale

100

172.77

Sale

100

173.51

Sale

50

173.02

Sale

100

173.02

Sale

50

173.03

Sale

200

173.24

Sale

64

174.12

Sale

50

174.01

Sale

50

174.01

Sale

100

173.96

Sale

96

174.04

Sale

50

174.03

Sale

100

173.33

Sale

100

173.13

Sale

100

171.53

Sale

100

170.97

Sale

100

171.01

Sale

96

171

Sale

4

170.8

Sale

100

173.87

Sale

100

172.76

Sale

100

172.45

Sale

98

172.38

Sale

50

173.09

Sale

50

173.09

Sale

3,442

172.525872

Sale

2

170.85

Sale

3,585

172.664508

Sale

196

170.92

Sale

1,168

172.896849

Sale

702

171.746177

Sale

1,388

170.895396

Sale

9,850

170.85

Sale

985

170.85

Sale

1,970

170.85

Sale

26

170.85

Sale

2,502

170.85

Sale

9,850

170.85

Sale

1,970

170.85

Sale

10,625

170.85

Sale

100

170.85

Sale

47

172.91

Sale

100

173.6

Sale

50

171.75

Sale

50

171.74

Sale

100

171.9

Sale

100

173.55

Sale

33

173.42

Sale

100

173.07

Sale

100

172.93

Sale

100

171.47

Sale

59

174.15

Sale

32

171.47

Sale

28

171.37

Sale

100

171.95

Sale

29

171.95

Sale

100

173.26

Sale

36

171.97

Sale

90

173.28

Sale

41

172.44

Sale

100

172.61

Sale

50

172.94

Sale

50

172.93

Sale

65

173.82

Sale

100

171.76

Sale

100

171.61

Sale

100

172.21

Sale

100

170.76

Sale

42

172.21

Sale

100

172.13

Sale

100

173.21

Sale

50

173.98

Sale

100

173.29

Sale

100

173.91

Sale

100

173.39

Sale

43

172.12

Sale

43

172.12

Sale

100

172.57

Sale

100

174.07

Sale

100

173.05

Sale

100

173.4

Sale

100

173.54

Sale

100

172.89

Sale

32

171.54

Sale

100

171.46

Sale

32

171.46

Sale

68

171.49

Sale

71

173.72

Sale

100

172.78

Sale

100

173.28

Sale

100

171.48

Sale

100

171.69

Sale

100

171.77

Sale

100

172.14

Sale

100

171.79

Sale

100

171.8

Sale

100

170.93

Sale

100

173.25

Sale

50

174.13

Sale

50

174.12

Sale

100

170.94

Sale

100

173.08

Sale

50

173.24

Sale

50

173.24

Sale

100

173.15

Sale

100

173.11

Sale

100

172.87

Sale

50

173.04

Sale

100

172.54

Sale

100

173.35

Sale

50

173.05

Sale

100

172.48

Sale

50

172.91

Sale

100

173.34

Sale

100

172.54

Total Purchases

687,392

 

Total Sales

58,773

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit USD

(Note 5)

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. 

If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)     Yes

 

Dateofdisclosure

25/03/2020

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ap23

 

SUPPLEMENTAL   FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT,   1997, TAKEOVER RULES, 2013

 

 

 

 

DETAILS   OF OPEN POSITIONS

 

(This   form   should   be   attached   to   Form   8.1(a)   & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS  (Note   1)

 

 

 

Productname,

e.g. call option

Written, orpurchased

Numberofrelevant securitiestowhichtheoptionorderivativerelates

Exercise price (Note 2)

Type, e.g.American,Europeanetc.

Expiry date

Listed Put Option

Sale

40,000

175

American options

15/01/2021

Listed Put Option

Sale

18,500

190

American options

15/01/2021

 

 

Notes

 

1.  Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.  For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the  

Rules. If in doubt, consult the Panel.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEKKPBDCBKKFNB

a d v e r t i s e m e n t